Medroxyprogesterone acetate does not antagonize estrogen-induced increases in endothelium-dependent vasodilation: potential clinical implications.
Determine the effect of combined 17beta-estradiol benzoate (E2) and medroxyprogesterone acetate (MPA) administration on endothelium-dependent vasorelaxation to acetylcholine (ACh). Prospective, ex vivo study. Academic research laboratory. Mature female rats. Ovariectomized rats received one of the following interventions daily for 3 days: [1] corn oil via IM injection, [2] E2 (20 microg/kg IM), or [3] E2 (20 microg/kg IM) and MPA (10 mg/kg IM). Basal release of nitric oxide (NO) and endothelium-dependent and endothelium-independent vasodilation from thoracic aortas obtained from each group. Estradiol treatment potentiated the endothelium-dependent relaxation to ACh when compared with the control group. Administration of MPA with E2 did not antagonize the beneficial effect of E2 on endothelium-dependent relaxation. Estradiol treatment alone or in combination with MPA did not affect endothelium-independent vasodilation as compared with the case of the control group. Administration of E2 resulted in increased basal NO release (assessed indirectly by measuring the constrictor response to N(G)-nitro-L-arginine [methyl ester (L-NAME)]) when compared with the case of the control group, and the addition of MPA to E2 did not alter the effect of E2 on basal NO release. Estradiol potentiates endothelium-dependent relaxant responses and increases basal endothelial NO release. Medroxyprogesterone acetate does not antagonize these effects of E2.